PERSONALIS INC (PSNL)

US71535D1063 - Common Stock

5.75  +0.49 (+9.32%)

After market: 5.86 +0.11 (+1.91%)

Fundamental Rating

2

Overall PSNL gets a fundamental rating of 2 out of 10. We evaluated PSNL against 56 industry peers in the Life Sciences Tools & Services industry. The financial health of PSNL is average, but there are quite some concerns on its profitability. PSNL is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

PSNL had negative earnings in the past year.
PSNL had a negative operating cash flow in the past year.
PSNL had negative earnings in each of the past 5 years.
PSNL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

PSNL has a worse Return On Assets (-38.12%) than 78.57% of its industry peers.
Looking at the Return On Equity, with a value of -54.83%, PSNL is doing worse than 66.07% of the companies in the same industry.
Industry RankSector Rank
ROA -38.12%
ROE -54.83%
ROIC N/A
ROA(3y)-34.43%
ROA(5y)-27.22%
ROE(3y)-52.21%
ROE(5y)-40.27%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PSNL's Gross Margin of 31.41% is on the low side compared to the rest of the industry. PSNL is outperformed by 67.86% of its industry peers.
PSNL's Gross Margin has declined in the last couple of years.
PSNL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-4.55%

More info and screens

4

2. Health

2.1 Basic Checks

PSNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSNL has more shares outstanding than it did 1 year ago.
PSNL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PSNL has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 0.01, we must say that PSNL is in the distress zone and has some risk of bankruptcy.
PSNL has a worse Altman-Z score (0.01) than 71.43% of its industry peers.
PSNL has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, PSNL is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.01
ROIC/WACCN/A
WACC11.67%

2.3 Liquidity

A Current Ratio of 4.68 indicates that PSNL has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.68, PSNL is doing good in the industry, outperforming 69.64% of the companies in the same industry.
A Quick Ratio of 4.44 indicates that PSNL has no problem at all paying its short term obligations.
PSNL's Quick ratio of 4.44 is fine compared to the rest of the industry. PSNL outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.68
Quick Ratio 4.44

More info and screens

6

3. Growth

3.1 Past

PSNL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.66%, which is quite impressive.
Looking at the last year, PSNL shows a very strong growth in Revenue. The Revenue has grown by 24.05%.
Measured over the past years, PSNL shows a quite strong growth in Revenue. The Revenue has been growing by 14.24% on average per year.
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)24.05%
Revenue growth 3Y-2.24%
Revenue growth 5Y14.24%
Sales Q2Q%40.89%

3.2 Future

Based on estimates for the next years, PSNL will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.99% on average per year.
PSNL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.30% yearly.
EPS Next Y30.48%
EPS Next 2Y21.61%
EPS Next 3Y16.67%
EPS Next 5Y16.99%
Revenue Next Year13.61%
Revenue Next 2Y8.71%
Revenue Next 3Y17.87%
Revenue Next 5Y36.3%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PSNL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PSNL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PSNL's earnings are expected to grow with 16.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.61%
EPS Next 3Y16.67%

More info and screens

0

5. Dividend

5.1 Amount

PSNL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PERSONALIS INC

NASDAQ:PSNL (12/20/2024, 4:14:06 PM)

After market: 5.86 +0.11 (+1.91%)

5.75

+0.49 (+9.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners41.36%
Inst Owner Change32.87%
Ins Owners19.92%
Ins Owner Change90.07%
Market Cap406.24M
Analysts81.67
Price Target7.19 (25.04%)
Short Float %5.59%
Short Ratio4.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.15%
Min EPS beat(2)-79.27%
Max EPS beat(2)36.97%
EPS beat(4)2
Avg EPS beat(4)-2.72%
Min EPS beat(4)-79.27%
Max EPS beat(4)37.32%
EPS beat(8)4
Avg EPS beat(8)0.35%
EPS beat(12)7
Avg EPS beat(12)2.11%
EPS beat(16)10
Avg EPS beat(16)3.16%
Revenue beat(2)2
Avg Revenue beat(2)16.56%
Min Revenue beat(2)14.93%
Max Revenue beat(2)18.2%
Revenue beat(4)3
Avg Revenue beat(4)8.77%
Min Revenue beat(4)-2.3%
Max Revenue beat(4)18.2%
Revenue beat(8)6
Avg Revenue beat(8)6.64%
Revenue beat(12)9
Avg Revenue beat(12)6.46%
Revenue beat(16)11
Avg Revenue beat(16)4.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)5.21%
EPS NQ rev (3m)21.89%
EPS NY rev (1m)-1.75%
EPS NY rev (3m)-18.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.15%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)4.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.64
P/FCF N/A
P/OCF N/A
P/B 2.44
P/tB 2.44
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS1.24
BVpS2.36
TBVpS2.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.12%
ROE -54.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.41%
FCFM N/A
ROA(3y)-34.43%
ROA(5y)-27.22%
ROE(3y)-52.21%
ROE(5y)-40.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-4.55%
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.31%
Cap/Sales 4.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.68
Quick Ratio 4.44
Altman-Z 0.01
F-Score5
WACC11.67%
ROIC/WACCN/A
Cap/Depr(3y)290.96%
Cap/Depr(5y)221.15%
Cap/Sales(3y)34.84%
Cap/Sales(5y)24.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y30.48%
EPS Next 2Y21.61%
EPS Next 3Y16.67%
EPS Next 5Y16.99%
Revenue 1Y (TTM)24.05%
Revenue growth 3Y-2.24%
Revenue growth 5Y14.24%
Sales Q2Q%40.89%
Revenue Next Year13.61%
Revenue Next 2Y8.71%
Revenue Next 3Y17.87%
Revenue Next 5Y36.3%
EBIT growth 1Y35.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.69%
EBIT Next 3Y11.53%
EBIT Next 5YN/A
FCF growth 1Y51.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.15%
OCF growth 3YN/A
OCF growth 5YN/A